Animal testing phase out

by Raoni

The gradual phase-out of in vivo testing is driven by ethical, scientific, and economic considerations. As biological products become more widespread, animal models are proving increasingly limited in their ability to predict human responses.

Both the EU and the US are stepping up efforts to promote New Approach Methodologies (NAMs), including 3D cell cultures, organ-on-chip systems, and advanced computational models.

The EMA firmly backs the 3Rs principle — Replacement, Reduction, Refinement — recommending that animals be used only as a last resort, in line with the European Roadmap for phasing out animal testing. (ref. EMA 3Rs; EU Roadmap)

The end goal is two-pronged: safeguarding patient safety and public health, while driving the development and uptake of scientifically reliable, internationally recognised NAMs and NATs (Non-Animal Technologies).

Before new methodologies can earn regulatory acceptance, they need to pass rigorous validation. Real hurdles remain — particularly in chronic toxicity, immunotoxicology, and neurotoxicology, where alternative methods still have ground to cover.

EFPIA adds a valuable perspective here, putting forward a structured framework tailored to the pharmaceutical industry’s specific needs. Their document outlines eight strategic actions built around a three-“basket” system, which ranks existing methods by how readily they can be replaced. (ref. EFPIA Recommendations on Phasing Out Animal Testing for Chemical Safety Assessments)


GFL Method: Monocyte Activation Test

At GEM FORLAB, we’ve brought in the Monocyte Activation Test (MAT) as a modern alternative to the traditional rabbit pyrogen test. Rather than relying on animals, the MAT uses human monocytes to detect fever-inducing substances — delivering comparable sensitivity with far greater relevance to human biology.

The method is fully recognised under European guideline Ph. Eur. 2.6.30 and aligns with the EMA’s 3Rs principles.


Organ-on-a-Chip

These miniature devices pair human cells with microfluidic technology to mimic the behaviour of real tissues and organs. They open the door to studying pharmacokinetics, toxicity, and complex biological interactions — all while cutting down on animal use and offering sharper predictive power than conventional models.


Did You Know?

Take a virtual tour of the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs). Their website has interactive quizzes and case studies that bring the 3Rs to life.

You may also like